Morgan Stanley’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$12M Buy
1,469,804
+682,724
+87% +$5.56M ﹤0.01% 3280
2025
Q1
$6.18M Buy
787,080
+237,166
+43% +$1.86M ﹤0.01% 3749
2024
Q4
$8.19M Sell
549,914
-164,542
-23% -$2.45M ﹤0.01% 3566
2024
Q3
$10.9M Buy
714,456
+268,576
+60% +$4.11M ﹤0.01% 3358
2024
Q2
$6.79M Sell
445,880
-429,002
-49% -$6.53M ﹤0.01% 3644
2024
Q1
$16.5M Sell
874,882
-527,908
-38% -$9.97M ﹤0.01% 2897
2023
Q4
$26.8M Buy
1,402,790
+793,804
+130% +$15.2M ﹤0.01% 3085
2023
Q3
$10.9M Sell
608,986
-11,548
-2% -$207K ﹤0.01% 3044
2023
Q2
$12.6M Buy
620,534
+64,453
+12% +$1.31M ﹤0.01% 2941
2023
Q1
$10.1M Buy
556,081
+9,732
+2% +$178K ﹤0.01% 3125
2022
Q4
$11.3M Buy
546,349
+193,288
+55% +$4M ﹤0.01% 2954
2022
Q3
$9.24M Sell
353,061
-230,635
-40% -$6.03M ﹤0.01% 3064
2022
Q2
$14.8M Buy
583,696
+333,066
+133% +$8.44M ﹤0.01% 2615
2022
Q1
$7.91M Sell
250,630
-1,183,774
-83% -$37.4M ﹤0.01% 3181
2021
Q4
$58M Buy
1,434,404
+1,300,591
+972% +$52.6M 0.01% 1233
2021
Q3
$4.67M Sell
133,813
-135,645
-50% -$4.73M ﹤0.01% 3791
2021
Q2
$7.4M Buy
269,458
+94,862
+54% +$2.6M ﹤0.01% 3352
2021
Q1
$4.9M Buy
174,596
+127,334
+269% +$3.58M ﹤0.01% 3431
2020
Q4
$1.23M Buy
47,262
+18,436
+64% +$479K ﹤0.01% 4539
2020
Q3
$494K Sell
28,826
-62,756
-69% -$1.08M ﹤0.01% 4652
2020
Q2
$2.27M Buy
91,582
+88,341
+2,726% +$2.18M ﹤0.01% 3483
2020
Q1
$45K Sell
3,241
-41,495
-93% -$576K ﹤0.01% 5502
2019
Q4
$452K Buy
44,736
+33,939
+314% +$343K ﹤0.01% 4983
2019
Q3
$98K Sell
10,797
-88,009
-89% -$799K ﹤0.01% 5451
2019
Q2
$785K Buy
98,806
+88,716
+879% +$705K ﹤0.01% 4359
2019
Q1
$125K Sell
10,090
-40,846
-80% -$506K ﹤0.01% 5295
2018
Q4
$549K Buy
50,936
+35,192
+224% +$379K ﹤0.01% 4728
2018
Q3
$220K Buy
15,744
+3,801
+32% +$53.1K ﹤0.01% 5414
2018
Q2
$146K Buy
11,943
+5,940
+99% +$72.6K ﹤0.01% 5646
2018
Q1
$93K Buy
+6,003
New +$93K ﹤0.01% 5725